Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 03/07/24
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline ProgressBusiness Wire • 03/07/24
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare ConferenceBusiness Wire • 02/26/24
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic FibrosisBusiness Wire • 02/22/24
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024InvestorPlace • 02/21/24
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024Business Wire • 02/20/24
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine BoosterPRNewsWire • 02/05/24
Why Arcturus Therapeutics Has A Promising Future With Innovative CF And COVID TreatmentsSeeking Alpha • 02/02/24
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine BoosterBusiness Wire • 12/21/23
Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 12/04/23
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adultsPRNewsWire • 11/28/23
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in AdultsBusiness Wire • 11/28/23
Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic FibrosisBusiness Wire • 11/27/23
From Financial Metrics To mRNA Milestones: Arcturus Therapeutics' Evolving JourneySeeking Alpha • 11/17/23
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline ProgressBusiness Wire • 11/14/23
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023Business Wire • 10/25/23